Marker Therapeutics Management
Management criteria checks 1/4
Marker Therapeutics' CEO is Juan Vera, appointed in May 2023, has a tenure of less than a year. total yearly compensation is $581.92K, comprised of 65.3% salary and 34.7% bonuses, including company stock and options. directly owns 2.88% of the company’s shares, worth €1.11M. The average tenure of the management team and the board of directors is 1.3 years and 5.7 years respectively.
Key information
Juan Vera
Chief executive officer
US$581.9k
Total compensation
| CEO salary percentage | 65.3% |
| CEO tenure | less than a year |
| CEO ownership | 2.9% |
| Management average tenure | 1.3yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$14m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$582k | US$380k | -US$20m |
Compensation vs Market: Juan's total compensation ($USD581.92K) is above average for companies of similar size in the German market ($USD391.56K).
Compensation vs Earnings: Insufficient data to compare Juan's compensation with company performance.
CEO
Juan Vera (42 yo)
less than a year
Tenure
US$581,923
Compensation
Dr. Juan F. Vera, MD, serves as Chief Executive Officer and President at Marker Therapeutics, Inc. since May 1, 2023. He has held various positions at the Center for Cell and Gene Therapy at Baylor College...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | less than a year | US$581.92k | 2.88% $ 1.1m | |
| Director of Administration | 7.6yrs | no data | no data | |
| Vice President of Human Resources | 1.3yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 2.4yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Head of Clinical Operations | less than a year | no data | no data | |
| Secretary | 7.7yrs | US$3.04m | no data | |
| Senior Director of Molecular Biology & Virology | no data | no data | no data |
1.3yrs
Average Tenure
Experienced Management: GX1's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.5yrs | US$581.92k | 2.88% $ 1.1m | |
| Independent Director | 4.7yrs | US$71.70k | 0.033% $ 12.9k | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Chairman | 5.5yrs | US$93.32k | 0.041% $ 16.0k | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Independent Director | 5.5yrs | US$67.20k | 8.77% $ 3.4m | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Director | 2.3yrs | US$62.71k | 0.0017% $ 647.5 |
5.7yrs
Average Tenure
61yo
Average Age
Experienced Board: GX1's board of directors are considered experienced (5.7 years average tenure).